-- 周三，韩国股市开盘走低，跟随华尔街走势。此前，OpenAI未能达到内部营收和用户目标，引发市场对人工智能行业的担忧。 韩国综合股价指数（KOSPI）下跌22.02点，开盘报6619点。韩国创业板指数（KOSDAQ）小幅上涨，开盘报1213.28点。 据《华尔街日报》报道，OpenAI首席财务官担忧公司若营收增长速度不足，可能无法支付未来合同款项，导致OpenAI的增长潜力受挫。 该报道引发其他人工智能股票和科技公司股价暴跌。 与此同时，尽管达成了停火协议，以色列周二仍对黎巴嫩南部发动了新的袭击，加剧了阿联酋退出欧佩克带来的石油危机。
Related Articles
Asia
JCET's Q1 Profit Jumps 43%, Revenue Slips 2%
JCET's (SHA:600584) net profit attributable to shareholders in the first quarter jumped 43% to 290.3 million yuan from 203.4 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 45% year on year to 0.16 yuan from 0.11 yuan.Operating revenue slipped 1.8% to 9.17 billion yuan from 9.34 billion yuan in the preceding year.The shares of the Chinese integrated circuit manufacturer dropped less than 3% during midday trade.
$SHA:600584
Asia
Update: G8 Education to Suspend Operation of Around 40 Centers, Shares Reach 16-Year Low
(Updates to add the stock movement in the sixth paragraph)G8 Education (ASX:GEM) plans to suspend the operation of around 40 of its centers as a result of an assessment of its network, according to a Wednesday Australian bourse filing.It will transition customers to one of the nearby centers and, where possible, redeploy team members. The firm will then consider longer-term options for those centers, including lease surrender, divestment, or other alternatives.The firm will also reorganize its support office structure and reduce its cost base.Its current spot occupancy as of April 24 came in at 56.4%, down 7% year-over-year, while year-to-date occupancy was 56.1%, down 7.9% versus the prior corresponding period.Occupancy across the early childhood education and care sector is lower compared to previous years due to sustained affordability pressures, falling birth rates, increased long-day care supply, and confidence impacted by serious child safety incidents, the filing noted.Its shares fell 25% in recent trading on Wednesday, earlier reaching a 16-year low.
$ASX:GEM
Asia
Fosun Pharmaceutical Reports 14% Higher Profit in Q1
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.
$HKG:2196$SHA:600196